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is moved and implanted to the injury 
site. A major cause of free flap transfer 
failures is technical problems associated 
with vascular anastomoses, such as intima 
lacerations, distortion of the vessels, and 
unequal intersuture distances.[2] Failure 
in anastomosis results in thrombosis and, 
ultimately, flap failure. The traditional 
surgical technique for microvascular anas-
tomosis involves stopping the blood flow 
using a clamp and holding the vessel 
sides next to each other and connecting 
them by using microvascular sutures 
(8-0 or 9-0 nylon) under a microscope.[3] 
Venous anastomosis can also be per-
formed using microvascular anastomotic 
coupling devices.[4] The anastomotic site is 
rigidly stented open by the external rings, 
which protects against vessel collapse or 
spasm. The coupler creates an intima-to-
intima contact without the use of sutures, 
which in turn reduces the chance of thrombosis.[5] Potential 
challenges associated with anastomotic couplers use include 
possible vessel twisting during coupling and potential intima 
trauma.[6] These couplers are also nondegradable and cannot 
be opened if necessary. Although effective for venous anasto-
moses, such couplers cannot be used for arterial anastomosis. 
Despite the significant advancements in the development of 
Microvascular anastomosis is a common part of many reconstructive and 
transplant surgical procedures. While venous anastomosis can be achieved 
using microvascular anastomotic coupling devices, surgical suturing is the 
main method for arterial anastomosis. Suture-based microanastomosis 
is time-consuming and challenging. Here, dissolvable sugar-based stents 
are fabricated as an assistive tool for facilitating surgical anastomosis. 
The nonbrittle sugar-based stent holds the vessels together during the 
procedure and are dissolved upon the restoration of the blood flow. The 
incorporation of sodium citrate minimizes the chance of thrombosis. The 
dissolution rate and the mechanical properties of the sugar-based stent can 
be tailored between 4 and 8 min. To enable the fabrication of stents with 
desirable geometries and dimensions, 3D printing is utilized to fabricate 
the stents. The effectiveness of the printed sugar-based stent is assessed 
ex vivo. The fabrication procedure is fast and can be performed in the 
operating room.
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1. Introduction
Vascular anastomosis is routinely performed during surgical 
procedures such as organ and tissue transplants as well as head, 
neck, and hand reconstruction.[1] For example, in 2015, more 
than one million reconstructive procedures were done in the 
US. In these surgeries, transplanted healthy tissue (free flap) 
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surgical glues, their use for vascular anastomosis is not feasible 
as they may leak into the blood vessels leading to blockage and 
thrombosis.[7] Thus, in arterial anastomosis, the only possible 
option is to connect the vessels through suturing, which can be 
time-consuming and challenging.
Suture-based anastomosis becomes more challenging when 
the blood vessels have different sizes, which is frequently 
observed in flap transplant and reconstructive surgeries.[8] In 
these cases, the outcome is highly skill-dependent and always 
carries the risk of vessel blockage or rupture. Therefore, devel-
oping an approach that facilitates suture-based anastomosis 
and makes the procedure less skill dependent is of great impor-
tance. One of the recent solutions that utilized a thermo-respon-
sive poloxamer gel that could keep the vessels open during the 
procedure could facilitate suture-based anastomosis;[9] however, 
it could not eliminate the risk of vessel blockage.
Stents are widely used in medicine for keeping lumens and 
conduits open and reliving obstructions permanently or for a 
specific period of time.[10] The majority of stents are permanent 
and fabricated from biocompatible metals such as titanium, 
cobalt–chromium, and stainless steel.[11] Recently, degradable 
stents have been fabricated using resorbable metals such as zinc 
and magnesium alloys as well as hard polymers.[12] However, 
there have been a limited number of materials for developing 
temporary stents for applications where the stents are only 
required for short periods of time (less than an hour). Among 
different materials used for engineering dissolvable stents, 
sugar-based compounds have shown promising results.[13] 
However, sugar-based materials have thrombogenesis poten-
tial.[14] This will be of great concern for microsurgeries where 
the variation in the cross-sectional area at the sent site is sig-
nificant. To address this challenge, in a study heparin was 
incorporated into sugar-based materials to prevent thrombosis 
in rabbit models.[15] However, the ability to tune the adhesion 
strength and dissolution rate of the stent was not addressed. In 
addition, using heparin at high concentrations can potentially 
have side effect especially in patients with low blood clotting 
factors.[16] Sodium citrate is a calcium chelator that is widely 
used in clinical practice for blood preservation. Sodium citrate 
toxicity range has been reported to be above 24 mg kg−1 day−1 
of body weight.[17] Thus for a human with an average mass of 
60 kg the toxic range is around 1440 mg. It has been shown 
that the citrate concentration of around 3% (w/w) is sufficient 
for clot prevention.[18] Thus, using sugar-based stent incorpo-
rated with sodium citrate could reduce its thrombogenicity.
Another limitation of the existing sugar-based stents is the 
fabrication of stents with desirable geometries and dimensions 
that can be used for nonequal vessel anastomosis, which is 
commonly seen in reconstructive surgeries. It is important to 
note that the size of blood vessels varies from patient to patient 
and thus the ability of fabricating stents with desired geometry 
and architecture would also significantly improve the success of 
such systems in microsurgeries.
The 3D printing technologies have emerged as promising 
tools for engineering complex yet highly defined architec-
tures.[19] The majority of extrusion-based printers are operating 
on melt-extrusion process. In 3D printing with melt-extrusion 
technology (MET), a polymer or solid material is melted, then 
extruded through the nozzle, and solidified on the printing pad 
to form a 3D architecture.[20] The resolution of the printing is 
dictated by the nozzle size, the viscosity of the molten polymer, 
the solidification rate, and moving speed of the nozzle. Printers 
with MET are normally working with hard polymers and 
printing of soft and glassy materials is extremely challenging. 
Sugar materials become glassy and highly viscous once melted. 
The solidification process of sugar glass is also gradual, which 
makes their use for 3D printing challenging. There are only a 
few examples in the literature that have successfully 3D-printed 
sugar-based constructs.[21]
In this study, sugar glass is used to 3D print stents with tun-
able dissolution rate that prevent clot formation and can hold 
tissues together during the anastomosis process. The sugar 
composition is optimized to achieve suitable tissue adhesion, 
dissolution rate, printability, and clot prevention. This approach 
can be later on applied for printing stents with the right dimen-
sions during the operation to improve the outcome of the 
process.
2. Results and Discussions
The goal of this study was to develop a dissolvable stent that 
could facilitate surgical anastomosis. Ideally, the stent should 
be nonbrittle to avoid its breakage into pieces in response to 
applied mechanical forces. Also, the stent should be adhesive 
to vessel walls to keep them in place during the surgical anas-
tomosis. The stents should also remain stable during the sur-
gical process, while they should dissolve rapidly following the 
blood flow restoration. Sugar-based structures have been previ-
ously used during vascular anastomosis. However, the utilized 
molding technique was not robust enough to enable the fab-
rication of different dimensions to fit different patients. In 
addition, uniform tubes could not be easily utilized for holding 
vessels of different sizes next to each other during the anas-
tomotic procedures. To address this challenge, we utilized 3D 
printers to fabricate sugar-based stents with desired dimen-
sions and structures. The fabrication process and the utiliza-
tion of the 3D-printed sugar-based stents are demonstrated in 
Figure 1a. The sugar-based materials were dissolved in water 
and placed in an oven under constant stirring until the majority 
of water (≈95% w/w) was evaporated. The molten sugar was 
then used as an ink to 3D-print tubular sugar-based stents. The 
fabricated sugar-based stents become sticky at the interface of 
moist surfaces. Once the vessels are placed over the stent, it 
holds them together and the surgeon can perform the anas-
tomosis (Figure 1b). Once the blood flow is restored they will 
dissolve quickly without leaving a trace. A library of cylindrical 
sugar-based stents with different diameters fabricated by 3D 
printing is shown in Figure 1c.
Previously fabricated sugar-based stents contained mainly 
sucrose and glucose, which are biocompatible and possess 
high water solubility. However, the combination of glucose and 
sucrose forms a brittle sugar glass and can break into pieces 
upon exposure to mechanical loads, which is not suitable 
for use as vascular stents. To solve this problem, plasticizers 
should be added to the composition and we selected to use dex-
tran, which has been approved for various food and medical 
uses by the United States Food and Drug Administration. The 
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addition of dextran significantly improved the ductility of the 
formed sugar glass. It is noteworthy that the understanding of 
the chemical interactions between various compounds could be 
beneficial if further modifications is needed, especially if the 
sugar-based composition does not offer desirable properties.
The designed stent only holds the tissue in place for a few 
minutes and then dissolves in blood flow. However, surgeons 
can use surgical glues to adhere the tissue together during the 
anastomosis process. The effect of glucose concentration on the 
adhesion properties was studied through a standard lap shear 
test. For this reason, pig femoral arteries were obtained and cut 
into pieces of 1 cm × 2 cm and were glued on a glass slide. 
On another glass slide, the molten sugar was added and then 
the two slides were gently pressed together. The slides were 
fixed on grips of a mechanical tester and a tangential force 
was applied. The results showed an improvement in the adhe-
sion strength by increasing glucose concentration (p  <  0.001; 
Figure 2a).
One of the key parameters in the design and the use of 
stents is their interaction with blood and potential thrombo-
genicity. We tested the thrombogenicity of sucrose and glucose, 
and the results showed a reduction in the clotting time by an 
increase of glucose content, while sucrose prevented blood clot 
(Figure S1, Supporting Information). However, since glucose 
was important in adhesion strength to the vessel surface, opti-
mizing the amount of sucrose and glucose in final composi-
tion to avoid thrombosis was important. The chance of clot 
formation in the presence of dynamic flow of blood could not 
be ruled out, especially in microvessels where the insertion 
of stents results in significant changes in hemodynamic. To 
avoid clotting effect of the engineered stent, we added sodium 
citrate, which is a calcium chelator and is currently used to 
prevent blood clot in clinic. Although the multicomponent 
nature of the sugar-based composition allows several methods 
for optimizing the properties of the stents, we only focused on 
the effect of ratio of components rather than their molecular 
weight. We varied the weight fractions of glucose (from 0 to 
50% w/w), sucrose (from 0 to 50%w/w), dextran (from 0 to 
20% w/w), and sodium citrate (from 0 to 5% w/w). The quali-
tative analysis showed that the composition of 11% (w/w) glu-
cose, 69% (w/w) sucrose, 17% (w/w) dextran (86 kDa), and 3% 
(w/w) sodium citrate offered suitable mechanical, adhesion, 
ductility, and blood clotting properties to be used for forming 
stents. As can be seen in Figure 2b,c, the stents made from 
the modified sugar-based composition showed low thrombo-
genecity upon their use in blood vessels. It should be noted 
that the color of the sugar-based composition was dark brown 
and it should not be misidentified as clots that are formed 
around them.
We also measured the rheological properties of the selected 
material system to present how its time-dependent (energy 
absorbing) properties varied over a temperature range of 20 to 
100 °C (Figure 2d). The viscous modulus, which indicates the 
capacity of material to dissipate mechanical energy, was found 
to be higher than the elastic modulus under shear loading. This 
could be interesting as the stent in situ would be subjected to 
dynamic loading by the blood vessels. At body temperature, the 
viscous and elastic moduli were in the range of 0.7–3.0 MPa. 
The elastic modulus and dynamic viscosity reduced logarithmi-
cally when the temperature rose up to 100 °C. This property of 
the material system was used to select an optimum tempera-
ture range for 3D printing of the construct. When the material 
is heated up in the nozzle, its viscosity (and elasticity) reduces 
to facilitate its flow through the nozzle. In our preliminary 
experiments, we found that a temperature range of 85–90 °C, 
which corresponded to a viscosity range of 50–70 Pa s, would 
be ideal for 3D printing with a nozzle gauge number of 
18G or 20G.
We compared the mechanical properties of stents fabricated 
using the above composition with the compositions used in 
Adv. Healthcare Mater. 2018, 7, 1800702
Figure 1. The fabrication and the utilization of sugar-based stents for vascular anastomosis. a) The process of preparation of sugar glass and its 3D 
printing into tubular stents. The mixture of sucrose, glucose, and dextran with water, after evaporating the majority of water in high temperatures 
(120–150 °C) were ready to 3D print. b) Schematic demonstration the utilization of 3D-printed sugar-based stents in surgical anastomosis. The sugar 
stent held the two vessels during suturing and was dissolved completely after blood supply restoration. c) Cylindrical sugar-based stents with various 
dimensions fabricated by 3D printing.
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ref. [22] (29% (w/w) glucose, 60% (w/w) sucrose, and 11% (w/w) 
dextran; Figure 2e). As can be seen, by adding dextran into the 
sugar compound, the compression strength of stents improved 
significantly (p <  0.001). None of the samples fabricated using 
the proposed composition broke during the mechanical tests 
and they only were deformed. Figure 2f shows the schematic 
of the compressive mechanical test on sugar-based stents. The 
role of the stent is only to keep the arteries in place during the 
surgical procedure and then the stent dissolves rapidly. There-
fore, the stent should only be stiff enough not to bend and 
deform during the anastomosis. The elastic modulus of our 
engineered sugar-based stent was 16 ± 2.3 MPa which is signifi-
cantly higher than the values for arteries (1.54 ± 0.33 MPa) and 
veins (3.11 ± 0.65 MPa) reported by other researchers.[23]
To mimic the operation of the engineered stent and mon-
itor its degradation rate, the stents were placed in transparent 
tubes, which were perfused by phosphate-buffered saline 
(PBS) at a rate of 20 mL min−1 (the flow rate comparable to 
small arteries; Figure 3a). At different time points, flow was 
stopped and the samples were removed and weighed, and the 
ratio of the dissolved mass was calculated. The results showed 
a gradual dissolution of the stent over time. We performed 
the experiments for tubes with an inner diameter of 3 mm 
and a variable outer diameter (Figure 3b). The results showed 
that the samples were dissolved between 4 and 6 min. During 
the perfusion time, the stents were gradually dissolved, while 
remained to the tube wall. The collected liquid was filtered to 
find broken pieces larger than 2 mm that were carried by the 
flow. During the experiments no indication of large pieces was 
observed. Although there might be some differences in flow 
pattern and consequently in the dynamic dissolution of sugar 
stents in Newtonian and non-Newtonian solutions, the differ-
ences will not be fundamentally different. To get close enough 
to in vivo conditions, we used the flow rate similar to blood 
flow and aqueous solution with temperature of 37 °C.
The total mass of a typical stent was around 600 mg and 
after dissolution of one sugar stent in whole blood volume, the 
variation in blood sugar level is negligible. However, during 
the dissolution time the local concentration of sugar could 
elevate for a few minutes. In addition, to ensure that no toxic 
compound is formed during the sugar-based material develop-
ment, the sugar-based composition was dissolved in culture 
media at different concentrations and was used to treat culture 
of human umbilical vein endothelial cells (HUVECs). After 
2 h, metabolic activity of the cells was measured using the 
PrestoBlue assay (Figure 4a). Results of the metabolic activity 
showed a high viability of endothelial cells after exposure to 
different concentrations of sugar for more than 2 h. As can 
be seen, the tested concentrations of sugar did not negatively 
impact cellular metabolic activity. After 24 h circulation of cul-
ture media containing 16% (w/v) sugar, live/dead assay and 
metabolic activity of cells showed no negative effect of high 
concentration of sugar on endothelial cells (Figure S2, Sup-
porting Information).
In the next step, the effect of sugar-based stents on HUVECs 
was tested under dynamic culture. For this reason, a closed-
loop fluidic circuit was developed in which HUVECs were 
cultured on a glass slide placed at the bottom of a bioreactor. 
Cells were exposed to flow-induced shear stress, which was 
mimicking their environment in the human body. Sugar-based 
Adv. Healthcare Mater. 2018, 7, 1800702
Figure 2. Evaluation of mechanical properties, adhesion strength, blood clotting time, and rheological properties of sugar-based composition. a) The 
effect of glucose concentration on the adhesion strength of sugar-based composition to atrial wall (n = 3). The glucose concentration in sugar composi-
tion had a direct relationship with adhesion strength of stents (***: p < 0.001). b,c) The clotting time assay of the sugar-based composition (11% (w/w) 
glucose, 69% (w/w) sucrose, 17% (w/w) dextran, and 3% (w/w) sodium citrate) shows that the optimized composition had low thrombogenecity (n = 3). 
d) Rheological characterization of the developed sugar-based stents. e) Comparative evaluation of the axial compressive strength of our engineered 
sugar-based stents (n = 3) and the stents made by the composition of ref. [22] with different diameters (n = 3) shows significantly higher mechanical 
properties of our sugar-based stents. f) The schematic illustration of sugar-based stents under compressive loads indicates the ductility of the constructs.
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stent was dissolved in 100 mL of culture media and poured 
in the reservoir to circulate through the system (Figure 4b). 
After 2 h circulation of the culture media containing sugar, 
cellular viability was visualized by the live/dead assay. In addi-
tion, to better understand the effect of each component of 
the sugar on HUVECs, similarly sized stents were fabricated 
from pure glucose and sucrose, were dissolved in 100 mL of 
culture media, and were perfused in separate bioreactors. The 
results showed that cells were alive, maintained their normal 
shape, and remained adherent to the glass slide (Figure 4c). 
Adv. Healthcare Mater. 2018, 7, 1800702
Figure 3. Assessment of the rate of sugar-based stent dissolution. a) The fluidic setup used for assessment of the dissolution of sugar-based stents 
and their dissolution pattern. b) The remaining weight of the engineered stents with an inner diameter of 3 mm and different outer diameter during 
PBS circulating (n = 3). The samples were gradually dissolved between 4 and 6 min and no large broken pieces were observed in the collected solution. 
c) Time-lapse images showing the gradual dissolution of the sugar stents and their adhesion to the tube wall during the stent dissolution.
Figure 4. The biocompatibility assessment of sugar-based stent and its components on endothelial cells. a) Viability ratio of endothelial cells estimated 
by measuring their metabolic activity in static condition. Different concentrations of sugar were dissolved and placed over the cells (n = 3). Results were 
analyzed using PrestoBlue kit. The results showed high cellular viability after 2 h of culture media circulation. b) Schematic illustration of the custom-
built bioreactor with a close-loop fluidic circuit. Endothelial cells were cultured on a glass slide and were placed inside the bioreactor. c) Fluorescence 
images of the live/dead assay performed on endothelial cells cultured within the bioreactor. Glucose-, sucrose-, and sugar-based stents were dissolved 
in culture media separately and put inside respected reservoir of microfluidic system. After 2 h of the dynamic experiment, the bioreactor was 
disassembled and endothelial cells were analyzed using live/dead assay kit. Live cells are presented as green and dead cells are shown in red color.
© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1800702 (6 of 9)
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The temperature of the solutions and materials in this study 
was kept less than 110° C for dissolving sucrose, glucose, and 
dextran in water, as well as remained water evaporation to avoid 
the potential formation of by-products such as furfural and het-
erocyclic, which usually are formed above 150 °C.[24] Regard-
less, our in vitro experiments confirmed the lack of toxicity in 
the formed sugar-based composition.
To assess the printability of the selected material system, 
we systematically investigated the influence of key 3D printing 
parameters on the generation of a continuous paste (Figure 5a). 
These key parameters included gauge number (nozzle diam-
eter), nozzle speed, and pneumatic air pressure while the per-
formance of 3D printing can be reported by the thickness of 
deposited straight line, or fiber. The air pressure dictated the 
pressure behind the nozzle while the material had a viscosity of 
50–100 Pa s. We then measured the thickness of printed fibers, 
as the printing resolution, for various parameters as shown 
in Figure 5b. The results showed that by changing the nozzle 
diameter (from 16 to 20G where higher gauge number led to 
clogging issues) and the nozzle movement speed (from 0.1 to 
5 mm s−1), the thickness of the deposited fibers could be tuned 
in the range of 0.9 to 4 mm. We could also print tubular stents 
with different sizes and different shapes. In particular, con-
nectors with different end sizes were printed that facilitate the 
anastomosis of nonequal sized vessels.
3D printing as a rapid fabrication technology provided a 
better control over the geometry of the fabricated constructs 
compared with conventional molding techniques. The viscosity 
of materials is a key factor in extrusion-based 3D printing. The 
temperature-dependent viscosity of our engineering materials 
allowed us to 3D print the sugar easily. The 3D printing tech-
nique offers the opportunity for rapid production of predefined, 
generally nonequal, anastomosis constructs in surgical rooms. 
Further technical advancement of 3D printing platforms, when 
interfaced with imaging modalities, may allow the fabrication 
of patient specific stents during the operation.
To assess the utility of the 3D-printed stents in facilitation 
of anastomosis, we performed two sets of experiments ex vivo. 
Pig femoral artery was explanted and cut into pieces and sugar-
based tube connectors with around 5 mm outer and 4 mm 
inner diameters were used to connect the pieces of tissue 
and suturing was performed by a surgeon. Our experiments 
showed that through the use of the stent, the suturing time 
was reduced from approximately 15 min to less than 5 min. 
During the first set of experiments, the stent was inserted to 
hold the vessels and the suture was applied to seal the open-
ings. We did not observe the slippage of the stent during the 
suturing process and the stents remained intact during the 
process. Upon the completion of the anastomosis, the vessels 
were perfused with aqueous solutions containing food dye with 
the rate of 35 mL min−1 and no leakage was observed. After a 
few minutes, the flow was stopped and the vessels were cut. 
The stent was completely dissolved and we did not observe any 
large pieces of sugar within the vessel or in the collected solu-
tion (Figure 6a).
During the second set of experiment, a thicker-walled stent 
with 5 ± 1 mm of outer diameter and 3 ± 1 mm of inner dia-
meter was used and after the first couple of sutures, aqueous 
solution was flowed through the vessels. No leakage was 
observed during the suturing process despite the continuation 
of the liquid perfusion. Immediately after suturing, the flow 
was stopped and the sutured were cut and the sugar stent was 
inspected. We noticed that the stent had become thinner while 
no pieces were broken (Figure 6b). The traditional surgical 
Adv. Healthcare Mater. 2018, 7, 1800702
Figure 5. Assessment of the printability of the optimized sugar composition. a) Schematic of the 3D printing process and 3D-printed sugar stents. 
b) Effects of speed and nozzle diameter on the printing resolution: fiber thickness versus three nozzle speeds (low: 0.1 mm s−1; medium: 0.5 mm s−1; 
high: 5 mm s−1) and pneumatic pressure (15–40 psi). Experiments were conducted three times for each condition.
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technique for microvascular anastomosis involves stopping 
the blood flow using a clamp, holding the vessel sides next 
to each other, and connecting them by using microvascular 
sutures under microscopic magnification.[25] Disadvantages of 
this method include the increased time needed for suturing, 
stopped sending the nutrition and oxygen to the tissues during 
suturing, and damaged live tissues during suturing. By using 
sugar-based stents during suturing, there is no need for stop-
ping the blood flow, which can potentially improve the outcome 
of the surgical procedure.
Overall, the proposed dissolvable stents facilitate vascular 
anastomosis. It is hemocompatible and does not induce throm-
bosis; its adhesion to the wet tissue eliminate combined by its 
rigidity, facilitates the suture-based microanastomosis.
3. Conclusions
Nonbrittle and anticlotting sugar-based composition was devel-
oped and used as the ink in commercially available 3D printers 
to create stent-like structures that could facilitate surgical 
anastomosis. The stents were completely dissolvable and their 
rate of dissolution and mechanical properties were tunable by 
changing the material composition. The sutures could hold the 
vessels in place during the suturing process and prevent the 
possibility of back-suturing during microsurgeries. The stents 
prevented thrombosis and blood leakage during the procedure. 
The 3D printing process that enabled us to fabricate constructs 
with desired shape and dimension was fast and a stent could 
be formed in less than few minutes. Thus, this technology can 
be used for printing the stents with correct dimension during 
the operation to improve the surgical outcome. In addition, the 
closed structure of the stents can prevent the leakage of sur-
gical glues into vessels and in future can facilitate the suture-
free anastomosis through combination with surgical glues. 
In future, animal studies should be conducted to ensure the 
effectiveness of the developed stents in facilitating surgical 
anastomosis.
4. Experimental Section
Materials: All chemical were purchased from Sigma-Aldrich while the 
cell culture medium and regents were obtained from Invitrogen unless 
mentioned otherwise.
Preparation of Sugar Glass and Stents: Two sets of sugar compounds 
were formed, one by mixing of 9.7 g glucose, 61 g sucrose, 15 g dextran, 
and 3 g sodium citrate. The incorporation of dextran improved the 
flexibility and incorporation of sodium citrate increased blood clotting 
time of the sugar-based composition. Another set of sugar compound 
was made from ref. [22] by mixing of 25 g glucose, 53 g sucrose, and 
10 g dextran. The mixture was dissolved in 50 mL of distilled water and 
the solution was stirred for 3 h at 130 °C to evaporate most of the water 
and form a liquid glass. The liquid glass was poured into glass syringe 
and was used in an extrusion-based printer (Allevi, Inc, Philadelphia, PA) 
to 3D print the engineered sugar glass. The printer involved a custom-
built reservoir connected to a high-pressure air source. The reservoir 
was heated up to 120 °C to lower the viscosity of sugar. Different shapes 
of sugar structures were prepared by the 3D printer under nitrogen 
pressure with pneumatic control through a 16-, 18-, and 20-gauge steel 
nozzle. Sugar tubes were also formed using molding in which molten 
sugar glass was added into PDMS molds and the samples were cured at 
170 °C for about 2 h.
Mechanical Characterization of the Material and Fabricated Stents: 
A standard lap shear stress was performed to assess the adhesion 
properties of the engineered sugar to native tissues. For this reason,  a pig 
femoral artery was purchased and was cut into 1 cm × 2 cm pieces which 
were glued onto glass slide. The sugar glass was poured and cured onto 
glass slides to cover a similar area. A sugar coated slide was placed on 
top of the tissue glued to the glass slide. The two slides were loaded into 
the grips of an Instron 5542 mechanical tester (Norwood, MA, USA). 
The samples were stretched and the adhesion strength was recorded.
The compressive mechanical properties of sugar-based stents were 
also determined. For this reason, cylindrical sugar-based stents were 
generated and were placed between the grips of the Instron mechanical 
tester and were compressed in axial direction.
Rheological Characterization of Sugar: The rheological properties of 
the sugar-based composition were measured using a controlled stress 
AR-G2 rheometer (TA Instruments, New Castle, DE) with a 40 mm 
diameter, parallel-plate geometry. The shear storage modulus (G′ ), the 
loss modulus (G″ ), and dynamic viscosity (/eta) were measured at a 
frequency of 1 Hz and an oscillatory strain of 0.05 (i.e., 5%). Temperature 
sweeps were performed using a Peltier plate (to heat up the bottom 
surface) over the range of 20 to 120 °C. Samples were equilibrated for 
Adv. Healthcare Mater. 2018, 7, 1800702
Figure 6. Ex vivo use of the sugar-based stents in suture-based anastomosis. a) A rapidly dissolvable stent was applied and pig arteries were connected 
by suturing. After that the vessels were perfused by aqueous solutions containing food dye at the rate of 35 mL min−1 and the stent was completely 
dissolved. No blood leakage was observed. b) A stent with longer dissolution time was used. The stent held the vessels together and perfusion was 
started. Suturing was continued without interruption of perfusion and no leakage was observed during and after anastomosis.
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1 min before testing and for 30 s at each subsequent temperature to 
ensure thermal homogeneity throughout the sample.
Clotting Time Assay: Approximately 50 mg of glucose, sucrose, or the 
sugar-based composition was placed at the bottom of each well in 48 
well flat-bottom plate. Mixture of 90% (v/v) citrated blood and 0.1 m 
calcium chloride was vortexed for 15 s and 100 µL of blood solution was 
deposited into sequential wells on a 48-well plate. Saline solution with 
concentration of 9 g L−1 was used to wash each well at selected time 
points to halt clotting. The liquid was immediately aspirated and washes 
repeated until the solution was clear, indicating removal of all soluble 
blood components. Final clotting time was marked in the well that 
formed a uniform clot, with no change in clot size in subsequent wells.
Assessment of the Dissolution Rate of Sugar Tubes: To mimic the 
operation of the engineered stent and monitor its degradation rate, 
the stents were placed in transparent acrylic tubes with the thickness 
of 2 mm, which were perfused by PBS with a rate of 20 mL min−1 (the 
flow rate comparable to small arteries). At different time points flow was 
stopped and the samples were removed and weighed and the ratio of 
the dissolved mass was calculated.
Biocompatibility Assessment of the Engineered Sugar-Based Stent: 
HUVECs were cultured in endothelial culture media obtained from Lonza 
and were used up to passage 9. Biocompatibility of the engineered sugar-
based stent was analyzed in static and dynamic conditions. In static tests, 
HUVECs were cultured in well plates. Sugar stents were dissolved in culture 
media and put over the endothelial cells. After 2 h, media containing 
sugar was aspired and the viability of the cells was analyzed using new 
media containing PrestoBlue reagent (Thermo Fisher) with the ratio of 
1:10. Cells were incubated for about half an hour at 37 °C. Thereafter, 
the media over the cells were collected and read by the plate reader.
Bioreactor for dynamic tests consisted of two parts, fluidic and holder 
of the glass slide. All bioreactor parts were made of polydimethylsiloxane 
(PDMS, Sylgard 184 Elastomer Kit, Dow Corning, weight ratio monomer 
to crosslinking agent 10:1). Uncured PDMS was poured over poly(methyl 
methacrylate) (PMMA) molds and put under desiccator until all of 
the bubbles inside the solution would be disappear. Then, the molds 
containing PDMS put inside +80 °C oven overnight till the PDMS would 
be totally cured. Slide glasses were cut into appropriate sizes to fit in the 
holder part of the bioreactor. All PDMS parts, tubes and slide glasses 
were put inside the autoclave machine in order to be sterile. HUVECs 
were cultured over the glass slides and put inside the incubator until 
a homogeneous monolayer of cells was formed. Next, glass slide was 
put inside the bioreactor and all parts were fixed using sterile screws. 
The bioreactor was connected to the reservoir using tubes which were 
appropriate for the peristaltic pump. Sugar, glucose, and sucrose stents 
were dissolved in 100 mL of culture media and added to the reservoir. 
The whole fluidic system was run for 2 h. After 2 h, the bioreactors were 
disassembled and glass slides containing HUVECs were removed and 
treated with LIVE/DEAD Viability/Cytotoxicity Kit (Theromo Fisher) 
for 15 min at 37 °C. At final stage, stained cells were analyzed using 
fluorescent microscope where live cells could be detected with green 
and dead cells could be identified with red labels.
Statistical Analysis: Each experiment was repeated three times and all 
data were presented by means ± standard deviation. Data were analyzed 
using one- and two-ways ANOVA and significant differences were 
presented as *p < 0.05, **p < 0.01, and ***p < 0.001.
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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